MorphoSys AG buy melinda
Summary
This prediction ended on 23.07.19 with a price of €103.40. With a performance of 10.00%, the BUY prediction by melinda for MorphoSys AG closed with a slight gain. melinda has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
MorphoSys AG | - | - | - | - |
iShares Core DAX® | -1.114% | 3.430% | 25.966% | 25.039% |
iShares Nasdaq 100 | 1.816% | 6.911% | 30.390% | 48.139% |
iShares Nikkei 225® | 2.113% | 5.501% | 23.404% | 11.979% |
iShares S&P 500 | 2.038% | 5.327% | 30.881% | 46.982% |
According to melinda what are the pros and cons of MorphoSys AG for the foreseeable future?
Pros
Cons
Comments by melinda for this prediction
In the thread Morphosys AG diskutieren
SecteurRecherche biotechnologique et médicale Agenda 13/03 | 22:00 Publication de résultats
Nombre d'employés : 326 personnes.
Stopped prediction by melinda for MorphoSys AG
MorphoSys AG
26.11.23
26.11.24
09.12.23
MorphoSys AG
12.06.22
12.06.23
13.06.23
MorphoSys AG
01.03.22
01.04.22
02.04.22
MorphoSys AG
05.12.21
05.12.22
01.03.22
MorphoSys AG
19.11.20
19.11.21
20.11.21
MorphoSys AG
20.07.20
04.11.21
19.11.20
MorphoSys AG
09.05.18
10.05.18
10.05.18
MorphoSys AG
12.02.18
19.03.18
19.03.18
MorphoSys AG
17.12.10
20.12.10
20.12.10
MorphoSys AG
06.07.10
16.12.10
16.12.10